Ashley Vo

8.6k total citations · 3 hit papers
129 papers, 5.7k citations indexed

About

Ashley Vo is a scholar working on Transplantation, Immunology and Nephrology. According to data from OpenAlex, Ashley Vo has authored 129 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Transplantation, 50 papers in Immunology and 33 papers in Nephrology. Recurrent topics in Ashley Vo's work include Renal Transplantation Outcomes and Treatments (79 papers), Renal Diseases and Glomerulopathies (33 papers) and Complement system in diseases (22 papers). Ashley Vo is often cited by papers focused on Renal Transplantation Outcomes and Treatments (79 papers), Renal Diseases and Glomerulopathies (33 papers) and Complement system in diseases (22 papers). Ashley Vo collaborates with scholars based in United States, France and Canada. Ashley Vo's co-authors include Stanley C. Jordan, Mieko Toyoda, Alice Peng, Joseph Kahwaji, Jua Choi, Nancy L. Reinsmoen, Rafael Villicana, Chih‐Hung Lai, Mark Haas and Dolly B. Tyan and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Ashley Vo

123 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation

2008 500 citations Ashley Vo, Mieko Toyoda et al. profile →
Update on the use of immunoglobulin in human disease: A review of evidence

2016 423 citations Stanley C. Jordan, Ashley Vo et al. profile →
Assessment of Tocilizumab (Anti–Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients

2017 245 citations Jua Choi, Ashley Vo et al. American Journal of Transplantation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ashley Vo United States	40	3.6k	2.0k	1.8k	1.2k	759	129	5.7k
Mieko Toyoda United States	37	2.6k 0.7×	1.5k 0.8×	1.5k 0.8×	906 0.8×	884 1.2×	110	4.8k
Caner Süsal Germany	36	2.8k 0.8×	1.8k 0.9×	1.2k 0.6×	719 0.6×	728 1.0×	192	4.4k
Maryvonne Hourmant France	34	2.0k 0.6×	1.2k 0.6×	1.4k 0.7×	1.1k 0.9×	791 1.0×	134	4.8k
Denis Glotz France	50	6.0k 1.7×	3.8k 1.9×	2.2k 1.2×	2.2k 1.9×	1.2k 1.6×	206	9.0k
Enver Akalin United States	39	2.0k 0.6×	1.4k 0.7×	1.2k 0.7×	632 0.5×	574 0.8×	120	4.2k
Jacques Dantal France	39	2.6k 0.7×	1.8k 0.9×	774 0.4×	1.3k 1.1×	1.2k 1.6×	147	5.8k
Dolly B. Tyan United States	31	2.6k 0.7×	2.2k 1.1×	2.7k 1.5×	632 0.5×	534 0.7×	74	5.6k
Hiroshi Toma Japan	41	2.0k 0.5×	2.0k 1.0×	1.2k 0.7×	760 0.7×	521 0.7×	315	5.8k
Luis Hidalgo Canada	40	4.9k 1.3×	2.9k 1.4×	1.7k 0.9×	1.5k 1.2×	884 1.2×	101	6.2k
René J. Duquesnoy United States	55	3.9k 1.1×	3.6k 1.8×	3.0k 1.6×	488 0.4×	1.4k 1.8×	236	8.3k

Countries citing papers authored by Ashley Vo

Since Specialization

Citations

This map shows the geographic impact of Ashley Vo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashley Vo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashley Vo more than expected).

Fields of papers citing papers by Ashley Vo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashley Vo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashley Vo. The network helps show where Ashley Vo may publish in the future.

Co-authorship network of co-authors of Ashley Vo

This figure shows the co-authorship network connecting the top 25 collaborators of Ashley Vo. A scholar is included among the top collaborators of Ashley Vo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashley Vo. Ashley Vo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shoji, Jun, Ashley Vo, Edmund Huang, et al.. (2025). Daratumumab for Treatment of Recurrent FSGS and PGNMID in Kidney Transplant. American Journal of Transplantation. 25(8). S881–S881.

Vo, Ashley, Edmund Huang, Xiaohai Zhang, et al.. (2025). Daratumumab (Anti-CD38) Desensitization in HLA Sensitized Patients: Long-Term Follow-Up. American Journal of Transplantation. 25(8). S267–S267.

Wisel, Steven A., Noriko Ammerman, Ashley Vo, et al.. (2023). Successful treatment of acute antibody-mediated rejection of liver allograft with imlifidase: A case report. SHILAP Revista de lepidopterología. 8(3). 100145–100145. 3 indexed citations

Pearl, Meghan, Patricia L. Weng, Jennifer Zhang, et al.. (2022). Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients. Clinical Transplantation. 36(8). e14734–e14734. 17 indexed citations

Jordan, Stanley C., Noriko Ammerman, Jua Choi, et al.. (2022). Evaluation of Clazakizumab (Anti–Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts. Kidney International Reports. 7(4). 720–731. 36 indexed citations

Ge, Shili, Maggie Chu, Joseph Kahwaji, et al.. (2022). Viral‐specific cytotoxic T‐cell responses in HLA‐sensitized kidney transplant patients maintained on everolimus and low‐dose tacrolimus. Transplant Infectious Disease. 24(2). e13805–e13805. 1 indexed citations

Vo, Ashley, Edmund Huang, Noriko Ammerman, et al.. (2021). Clazakizumab for desensitization in highly sensitized patients awaiting transplantation. American Journal of Transplantation. 22(4). 1133–1144. 30 indexed citations

Reese, Peter P., Olivier Aubert, Maarten Naesens, et al.. (2020). Assessment of the Utility of Kidney Histology as a Basis for Discarding Organs in the United States: A Comparison of International Transplant Practices and Outcomes. Journal of the American Society of Nephrology. 32(2). 397–409. 49 indexed citations

Jordan, Stanley C., Noriko Ammerman, Mieko Toyoda, et al.. (2020). CLAZAKIZUMAB (ANTI-IL-6 MONOCLONAL) TREATMENT OF PATIENTS WITH CHRONIC & ACTIVE ANTIBODY-MEDIATED REJECTION POST-KIDNEY TRANSPLANTATION (NCT03380377). Transplantation. 104(S3). S67–S68. 4 indexed citations

10.

Jordan, Stanley C., Jua Choi, Irene Kim, et al.. (2016). Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection. Transplantation. 101(1). 32–44. 201 indexed citations

11.

Vo, Ashley, Aditi Sinha, Mark Haas, et al.. (2015). Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization. Transplantation. 99(7). 1423–1430. 60 indexed citations

12.

Jordan, Stanley C., Jua Choi, & Ashley Vo. (2015). Achieving Incompatible Transplantation through Desensitization: Current Perspectives and Future Directions. Immunotherapy. 7(4). 377–398. 17 indexed citations

13.

Vo, Ashley, Jua Choi, Kristen Cisneros, et al.. (2014). Benefits of Rituximab Combined With Intravenous Immunoglobulin for Desensitization in Kidney Transplant Recipients. Transplantation. 98(3). 312–319. 91 indexed citations

14.

Kahwaji, Joseph, Dechu Puliyanda, James Mirocha, et al.. (2013). Polyomavirus BK Viremia in Kidney Transplant Recipients After Desensitization With IVIG and Rituximab. Transplantation. 97(7). 755–761. 28 indexed citations

15.

Toyoda, Mieko, Shili Ge, Elina Suviolahti, et al.. (2011). IFNγ production by NK cells from HLA-sensitized patients after in vitro exposure to allo-antigens. Transplant Immunology. 26(2-3). 107–112. 21 indexed citations

16.

Toyoda, Mieko, et al.. (2010). Cellular allo reactivity against paternal HLA antigens in normal multiparous females as detected by intracellular cytokine flow cytometry remains elevated over years despite diminution of anti-HLA antibody levels. Transplant Immunology. 23(3). 133–140. 7 indexed citations

17.

Jordan, Stanley C., Alice Peng, & Ashley Vo. (2008). Therapeutic Strategies in Management of the Highly HLA-Sensitized and ABO-Incompatible Transplant Recipients. Contributions to nephrology. 162. 13–26. 25 indexed citations

18.

Jordan, Stanley C., et al.. (2006). Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation.. PubMed. 117. 199–211; discussion 211. 27 indexed citations

19.

Jordan, Stanley C., Ashley Vo, Cynthia C. Nast, & Dolly B. Tyan. (2003). Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience.. PubMed. 193–8. 20 indexed citations

20.

Bunnapradist, Suphamai, et al.. (2002). Treatment of Parvovirus B-19 (PV B-19) Infection Allows for Successful Kidney Transplantation Without Disease Recurrence. American Journal of Transplantation. 2(5). 425–428. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact